The global assisted reproductive technology market size was valued at USD 29.59 billion in 2025 and is projected to attain USD 49.30 billion by 2033, growing at a CAGR of 6.59% during 2025-2033. The growth is primarily driven by rising infertility rates, technological advancements in reproductive medicine, and increasing awareness of fertility treatments. Supportive policies and the expansion of specialized clinics further support the market's growth globally.
Assisted Reproductive Technology includes all medical procedures that are used in treating infertility and allowing individuals or couples to conceive when it is not possible, or unlikely, through natural conception. ART involves the manipulation of eggs, sperm, or embryos outside the human body and includes techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), cryopreservation of gametes and embryos, oocyte or sperm donation programs, and gestational surrogacy. These procedures may be used to treat infertility caused by hormonal imbalances, fallopian tube blockages, low sperm quality, endometriosis, age-related reproductive decline, or unexplained infertility. ART also supports individuals with genetic concerns, LGBTQ+ families, and those choosing fertility preservation for medical or personal reasons.
Because of increasing infertility rates, delayed parenting, increased awareness of reproductive options, and medical technological advances, the demand for ART has grown significantly worldwide. Innovations in embryo culture systems, genetic screening, and cryotechnology have significantly improved success rates. Fertility clinics continue to globally expand to meet demand, which is increasingly strong in North America and Europe and rapidly emerging in Asia and the Middle East. As reproductive health discussions become more open and socially accepted, ART continues to become an essential solution to modern family building.
Headquarters: United States of America
Thermo Fisher Scientific Inc is a leading supplier of a broad range of analytical instruments, life sciences solutions, and specialty diagnostics. The company's product portfolio encompasses laboratory essentials, advanced instruments for clinical applications, chromatography and mass spectrometry systems, and molecular biology instruments. Thermo Fisher customers include pharmaceutical and biotechnology companies, research institutions, universities, and government agencies. The company sells its products under various brands such as: Thermo Scientific, Applied Biosystems, and Fisher Scientific, among others, through direct sales, customer service, e-commerce sites, and third-party distributors.
Headquarters: Japan
Sumitomo Mitsui Financial Group Inc is a financial holding company. The company offers various financial services, such as commercial banking, leasing, securities, and consumer finance. Its major products and services include financing, investment management, risk hedging, settlement, M&A advisory, digital services, and leasing through subsidiaries. The company provides its services to corporate customers, SMEs, and individual customers of most industries. SMFG operates through a network of branches, representative offices, ATMs, and online portals. The company operates in Europe, the Middle East, the Americas, and Asia-Pacific.
Headquarters: United States of America
The Cooper Companies Inc (Cooper) is a medical device company focused on ophthalmology and surgical markets. It designs, manufactures, and distributes single-use, two-week, and monthly contact lenses to treat myopia, astigmatism, ocular dryness, and eye fatigue. Its product portfolio comprises spherical, toric, and multifocal contact lenses. Cooper also provides fertility and women's health products like ART devices, needles, catheters, and micropipettes. It sells its products under Biofinity, MyDay, clariti 1 day, Proclear, and Biomedics brands. The company operates through a network of manufacturing, cryostorage, R&D, and distribution facilities across the Americas, EMEA, and Asia Pacific.
Headquarters: Japan
Fujifilm Holdings Corp is a developer, manufacturer, and seller of healthcare solutions, material solutions, and imaging systems. Its offerings include various products and services, such as medical devices, semiconductor materials, instant cameras, color film and chemicals, photofinishing equipment, inkjet printheads, office solutions, and imaging equipment. The various products of Fujifilm cater to a wide array of customers across industries such as healthcare, electronics, and business communications, where they are used for purposes that include medical diagnostics, industrial efficiency, and digital transformation. The company sells its products to customers through a direct sales channel using a network of channel partners and distribution networks. The company has a presence in the Americas, Europe, Africa, and Asia-Pacific.
Headquarters: Germany
Merck KGaA (Merck) is a science and technology company and subsidiary of E. Merck KG. The company discovers, develops, and manufactures prescription drugs for treating cancer, multiple sclerosis, and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Its products include lab water systems; gene editing tools; cell lines, antibodies; microbiology and biomonitoring products; test assays; analytical reagents; and flow cytometry kits and instruments; and end-to-end systems. Merck sells its products and services to customers in research and diagnostic laboratories, as well as to biotech and pharmaceutical companies and life sciences companies, among others, in Europe, the Americas, Asia-Pacific, the Middle East, and Africa.
Vitrolife AB enjoys strong competitive strengths in the ART market with its highly specialized product portfolio, strong research base, and global clinical trust. The company provides advanced solutions for embryo culture, cryopreservation, genetic testing, and laboratory systems, making it one of the most comprehensive providers in the fertility sector. Vitrolife’s products are known for quality, precision, and consistency - key requirements for improving IVF success rates. Focus on continuous innovation, together with collaboration with IVF laboratories and research institutions, has further consolidated this company's leadership in evidence-based reproductive technologies. With over 100 countries comprising its global presence, Vitrolife benefits from diversified access to markets and deep customer relationships. Strategic acquisition of complementary reproductive technology firms strengthened its portfolio and technological capability, offering Vitrolife a trusted and influential position across the world in the ART ecosystem.
With a dedicated ART segment, Cosmos Biomedical Ltd. has key strengths in supplying and serving customers reliably in the ART market. This company supplies some of the consumables and laboratory requirements needed in the operation of IVF clinics, such as embryo transfer devices, culture media, and cryopreservation equipment. With a focused approach to product affordability and high quality, Cosmos Biomedical is considered a main supplier in the fertility industry, which requires economically attractive, yet dependable, products and services. Cosmos Biomedical has good relationships with embryologists and healthcare professionals, allowing for product design to meet clinical demands. The simplified distribution network ensures prompt delivery and thereby maximizes operational convenience at the clinic level. With strategic attention to regulatory compliance and safety standards, the Company has an opportunity to be credible in local and international marketplaces. This will enable Cosmos Biomedical to position itself as a dependable provider in this rapidly expanding global fertility market.
Assisted Reproductive Technology includes all medical procedures that are used in treating infertility and allowing individuals or couples to conceive when it is not possible, or unlikely, through natural conception. ART involves the manipulation of eggs, sperm, or embryos outside the human body and includes techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), cryopreservation of gametes and embryos, oocyte or sperm donation programs, and gestational surrogacy. These procedures may be used to treat infertility caused by hormonal imbalances, fallopian tube blockages, low sperm quality, endometriosis, age-related reproductive decline, or unexplained infertility. ART also supports individuals with genetic concerns, LGBTQ+ families, and those choosing fertility preservation for medical or personal reasons.
Because of increasing infertility rates, delayed parenting, increased awareness of reproductive options, and medical technological advances, the demand for ART has grown significantly worldwide. Innovations in embryo culture systems, genetic screening, and cryotechnology have significantly improved success rates. Fertility clinics continue to globally expand to meet demand, which is increasingly strong in North America and Europe and rapidly emerging in Asia and the Middle East. As reproductive health discussions become more open and socially accepted, ART continues to become an essential solution to modern family building.
Top Manufacturers
Thermo Fisher Scientific Inc.
Founded: 2006Headquarters: United States of America
Thermo Fisher Scientific Inc is a leading supplier of a broad range of analytical instruments, life sciences solutions, and specialty diagnostics. The company's product portfolio encompasses laboratory essentials, advanced instruments for clinical applications, chromatography and mass spectrometry systems, and molecular biology instruments. Thermo Fisher customers include pharmaceutical and biotechnology companies, research institutions, universities, and government agencies. The company sells its products under various brands such as: Thermo Scientific, Applied Biosystems, and Fisher Scientific, among others, through direct sales, customer service, e-commerce sites, and third-party distributors.
Sumitomo Mitsui Financial Group, Inc.
Founded: 2002Headquarters: Japan
Sumitomo Mitsui Financial Group Inc is a financial holding company. The company offers various financial services, such as commercial banking, leasing, securities, and consumer finance. Its major products and services include financing, investment management, risk hedging, settlement, M&A advisory, digital services, and leasing through subsidiaries. The company provides its services to corporate customers, SMEs, and individual customers of most industries. SMFG operates through a network of branches, representative offices, ATMs, and online portals. The company operates in Europe, the Middle East, the Americas, and Asia-Pacific.
CooperSurgical, Inc.
Founded: 1990Headquarters: United States of America
The Cooper Companies Inc (Cooper) is a medical device company focused on ophthalmology and surgical markets. It designs, manufactures, and distributes single-use, two-week, and monthly contact lenses to treat myopia, astigmatism, ocular dryness, and eye fatigue. Its product portfolio comprises spherical, toric, and multifocal contact lenses. Cooper also provides fertility and women's health products like ART devices, needles, catheters, and micropipettes. It sells its products under Biofinity, MyDay, clariti 1 day, Proclear, and Biomedics brands. The company operates through a network of manufacturing, cryostorage, R&D, and distribution facilities across the Americas, EMEA, and Asia Pacific.
Fujifilm Holdings Corporation
Founded: 1934Headquarters: Japan
Fujifilm Holdings Corp is a developer, manufacturer, and seller of healthcare solutions, material solutions, and imaging systems. Its offerings include various products and services, such as medical devices, semiconductor materials, instant cameras, color film and chemicals, photofinishing equipment, inkjet printheads, office solutions, and imaging equipment. The various products of Fujifilm cater to a wide array of customers across industries such as healthcare, electronics, and business communications, where they are used for purposes that include medical diagnostics, industrial efficiency, and digital transformation. The company sells its products to customers through a direct sales channel using a network of channel partners and distribution networks. The company has a presence in the Americas, Europe, Africa, and Asia-Pacific.
Merck KGaA
Founded: 1668Headquarters: Germany
Merck KGaA (Merck) is a science and technology company and subsidiary of E. Merck KG. The company discovers, develops, and manufactures prescription drugs for treating cancer, multiple sclerosis, and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Its products include lab water systems; gene editing tools; cell lines, antibodies; microbiology and biomonitoring products; test assays; analytical reagents; and flow cytometry kits and instruments; and end-to-end systems. Merck sells its products and services to customers in research and diagnostic laboratories, as well as to biotech and pharmaceutical companies and life sciences companies, among others, in Europe, the Americas, Asia-Pacific, the Middle East, and Africa.
Product Launches in the Assisted Reproductive Technology Market
Progyny Inc.
Oct 2025, Progyny, Inc. announced the launch of its pregnancy, postpartum, and menopause programs for global employers, starting January 2026. These complement the company’s existing, market-leading global fertility and family building offerings, thus providing multi-national employers with a continuum of integrated services. Progyny’s localized global expertise and member-first experience now support unmet needs across pivotal women’s and family life stages.Cook Medical Inc.
Oct 2024, Cook Medical announces the availability of the NestVT Vitrification Device in the United States. This is a safe device for embryos and oocytes during vitrification, cryo-storage, and relocation. Concurrently with launching this novel product, Cook transforms into a trusted partner for in-vitro fertilization (IVF) by offering simulation training and education courses to support the entire process of IVF.SWOT Analysis of the Company
Vitrolife AB
Strengths: Highly specialized product portfolio, strong research foundation, and global clinical trust.Vitrolife AB enjoys strong competitive strengths in the ART market with its highly specialized product portfolio, strong research base, and global clinical trust. The company provides advanced solutions for embryo culture, cryopreservation, genetic testing, and laboratory systems, making it one of the most comprehensive providers in the fertility sector. Vitrolife’s products are known for quality, precision, and consistency - key requirements for improving IVF success rates. Focus on continuous innovation, together with collaboration with IVF laboratories and research institutions, has further consolidated this company's leadership in evidence-based reproductive technologies. With over 100 countries comprising its global presence, Vitrolife benefits from diversified access to markets and deep customer relationships. Strategic acquisition of complementary reproductive technology firms strengthened its portfolio and technological capability, offering Vitrolife a trusted and influential position across the world in the ART ecosystem.
Cosmos Biomedical Ltd.
Strengths: Specialization in fertility-focused medical devices, reliable supply capabilities, and a customer-centered service modelWith a dedicated ART segment, Cosmos Biomedical Ltd. has key strengths in supplying and serving customers reliably in the ART market. This company supplies some of the consumables and laboratory requirements needed in the operation of IVF clinics, such as embryo transfer devices, culture media, and cryopreservation equipment. With a focused approach to product affordability and high quality, Cosmos Biomedical is considered a main supplier in the fertility industry, which requires economically attractive, yet dependable, products and services. Cosmos Biomedical has good relationships with embryologists and healthcare professionals, allowing for product design to meet clinical demands. The simplified distribution network ensures prompt delivery and thereby maximizes operational convenience at the clinic level. With strategic attention to regulatory compliance and safety standards, the Company has an opportunity to be credible in local and international marketplaces. This will enable Cosmos Biomedical to position itself as a dependable provider in this rapidly expanding global fertility market.
Recent Developments in the Assisted Reproductive Technology Market
Natera, Inc.
August 2025, Natera, Inc announced the launch of Fetal Focus, its NIPT for inherited conditions. This launch is supported by data from the EXPAND study - a large, prospective, blinded clinical trial. The study initiated in 2023 has enrolled approximately 1,300 participants to date, reflecting a representative, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. The EXPAND study is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing.Sartorius AG
September 2025, Biotechnology company Sartorius extended the site of the French sub-group, Sartorius Stedim Biotech, located in Illkirch near Strasbourg. The state-of-the-art plant introduces pharmaceutical-grade (GMP) manufacturing of transfection reagents, which are important building blocks in the production of viral vectors for new treatments. This investment reinforces Sartorius' commitment to support its customers regarding the development and manufacturing of cell and gene therapies in one of the most promising and fastest-growing biopharmaceutical segments.Sustainability Goal
Genea Biomedx Group
Genea Biomedx Group incorporates sustainability into its fertility technology operations through responsible manufacturing, including energy efficiency in all laboratory systems and equipment that minimizes wastes from IVF procedures. The company focuses on durability, reusable components, and long-lasting product design to decrease the use of disposable plastics and material waste within fertility laboratories. Genea Biomedx also innovates to enhance efficiency, translating into fewer repeated procedures and lower consumption of resources per successful treatment cycle. Environmental considerations are integrated with product development, packaging reduction, and logistics optimization. Besides this, the company shares in education and responsible practice guidelines that allow clinics to operate with minimal chemical waste and a safer laboratory environment. Genea Biomedx is committed to creating sustainable fertility outcomes where technological advancement goes hand in hand with environmental responsibility and ethical reproductive care.IVF Holland NV
At IVF Holland NV, sustainability means a continuous drive toward eco-friendly product development, responsible sourcing, and carbon footprint reduction in fertility-related production processes. Indeed, the company invests in laboratory systems and consumables that are designed to be efficient, safe, and generate minimal single-use waste. IVF Holland NV supports various initiatives aimed at optimizing energy use within clinical settings through the use of efficient incubators and smart workflow systems that minimize resource waste. The company adheres to strict ethical and environmental compliance policies that ensure the responsible development and deployment of reproductive technologies. This even extends to training programs for clients on how best to enhance operational sustainability in clinics through efficient use of inventory, waste management, and energy-efficient management of laboratories. By combining environmental stewardship with quality reproductive solutions, IVF Holland NV aims to contribute to a more sustainable future in the global fertility and reproductive healthcare industry.Market Segmentation
Assisted Reproductive Technology Market
- Historical Trends
- Forecast Analysis
Market Share Analysis - Assisted Reproductive Technology Market
Thermo Fisher Scientific Inc
Overview
- Company History and Mission
- Business Model and Operations
Workforce
Key Persons
- Executive Leadership
- Operational Management
- Division Leaders
- Board Composition
Recent Development & Strategies
- Mergers & Acquisitions
- Partnerships
- Investments
Sustainability Analysis
- Renewable Energy Adoption
- Energy-Efficient Infrastructure
- Use of Sustainable Packaging Materials
- Water Usage and Conservation Strategies
- Waste Management and Circular Economy Initiatives
Product Analysis
- Product Profile
- Quality Standards
- Product Pipeline
- Product Benchmarking
Strategic Assessment: SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Revenue Analysis
The above information will be available for all the following companies:
- Thermo Fisher Scientific Inc
- Sumitomo Mitsui Financial Group, Inc.
- CooperSurgical, Inc.
- Fujifilm Holdings Corporation
- Merck KGaA
- Progyny Inc.
- Cosmos Biomedical Ltd.
- Vitrolife AB
- Cook Medical Inc.
- Natera, Inc.
- Sartorius AG
- Organon & Co.
- Ferring Pharmaceuticals
- Genea Biomedx Group
- IVF Holland NV
- ReproMed Systems Inc.
- Ovation Fertility
- CooperGenomics
- Xytex CryoInternational
- IVI Fertility Network
Table of Contents
1. Assisted Reproductive Technology Market
3. Thermo Fisher Scientific Inc.
The above information will be provided for all the following companies:
Companies Mentioned
- Thermo Fisher Scientific Inc
- Sumitomo Mitsui Financial Group, Inc.
- CooperSurgical, Inc.
- Fujifilm Holdings Corporation
- Merck KGaA
- Progyny Inc.
- Cosmos Biomedical Ltd.
- Vitrolife AB
- Cook Medical Inc.
- Natera, Inc.
- Sartorius AG
- Organon & Co.
- Ferring Pharmaceuticals
- Genea Biomedx Group
- IVF Holland NV
- ReproMed Systems Inc.
- Ovation Fertility
- CooperGenomics
- Xytex CryoInternational
- IVI Fertility Network
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 29.59 Billion |
| Forecasted Market Value ( USD | $ 49.3 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
